Looking at historical and current market caps placed on such stocks as XOMA, MNKD, ACAD, AMRN, HGSI, ARNA, and VVUS I think a strong case can be made for placing a current valuation on AMBS as stated.
Obviously this is on the very low side of where I expect it will be in six months. I think it's only a matter of time before news is released that will move the share price to the level that I've stated.
It will soon be very evident how undervalued the company is currently.
"Patience is a virtue."
For those of you that think a $186,000,000 market cap is unreasonable that is your choice. Over the years I've seens number of bio-techs with substantially less potential than AMBS that had market caps in excess of $250,000,000.
Mannkind's market cap is currently in excess of $2,800,000,000 on a fully diliuted basis and it is about eight months away from a third F.D.A. decision on Afrezza with no guarantee that Afrezza will be approved. Which is a better investment currently? AMBS or MNKD? I expect AMBS offers 500% upside over the next six months where as MNKD is likely to be at or below its current price in six months.
Inetresting weeks and months ahead for AMBS shareholders.